Holen Sie sich die Stockscreener-App
0.6627
0.26%
0.0017
Handel nachbörslich:
.70
0.0373
+5.63%
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade
Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade
Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus
Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget
Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com
Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade
Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan
Artelo Biosciences Q2 Net Income USD -2.4 Mil - Moomoo
Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain - Stock Titan
Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan
Artelo Biosciences Q2 FY26 net loss narrows 24.65% to USD 2.43 million - Bitget
Artelo Biosciences (ARTL) Advances 6.34% to $0.75 as Micro-Cap Biotech Tests Key ResistanceDebt Free Companies - vinanet.vn
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo doses first patient in glaucoma study for ART27.13 - Investing.com
Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure - Stock Titan
Price to book forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Artelo Biosciences (ARTL) Slips to $0.73 as Biotech Names Face Renewed Selling PressureBlue Chip Entry Points - vinanet.vn
ARTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Artelo Biosciences (ARTL) Rises 1.96% as Shares Hold Between Key Support and ResistanceWide Range Bar - vinanet.vn
Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - TradingView
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences (ARTL) Edges Higher Near Resistance: Key Levels to WatchALMA Signal - dars.gov.et
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - marketscreener.com
New Analysis of Over 50 Studies Showed that All the - GlobeNewswire
Review of 50+ CBD studies finds drug interactions in retail products - Stock Titan
Form 4 Artelo Biosciences Inc For: 21 July By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director - Stock Titan
Artelo Biosciences (ARTL) grants small stock option award to director - Stock Titan
Artelo Biosciences (ARTL) awards 136-share stock option grant - Stock Titan
Artelo Biosciences grants options to director | ARTL Insider Trading - Stock Titan
ARTL Q4 2025 Earnings: Significant EPS Surprise Despite No RevenueEarnings Sentiment Score - dars.gov.et
Artelo Biosciences Q4 2025 Earnings: EPS Surprises Significantly vs. EstimatesRetail Earnings Report - dars.gov.et
Artelo Biosciences (ARTL) Proxy filing Summary - Quartr
Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies - Stock Titan
Artelo Biosciences (ARTL) AGM 2026 Summary - Quartr
ARTL: All proposals, including director elections and share increases, were approved - TradingView
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo presents preclinical data on osteoarthritis pain drug - Investing.com UK
Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P - GuruFocus
Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions - marketscreener.com
Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen - Quiver Quantitative
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - The Manila Times
These stocks are moving in today's after hours session - ChartMill
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 - The Manila Times
Every Artelo proxy helps reach quorum for July 17 meeting - Stock Titan
Artelo Biosciences reminds shareholders to vote before July 17 meeting - scanx.trade
8.37%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):